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Abstract: Non-ST elevation acute coronary syndrome (NSTE-ACS) refers to a cardiovascular 
disorder characterized by intracoronary thrombus formation on a disrupted atherosclerotic plaque 
with partial or transient occlusion. Generation of thrombin resulting from exposure of collagen 
leads to activation of platelets and conversion of ﬁ  brinogen to ﬁ  brin, thus forming a platelet-rich 
thrombus. The main therapeutic objective is to protect the patient from thrombotic complica-
tions, independent of the choice of antithrombotic agents. The management of NSTE myocardial 
infarction (MI) is constantly evolving. For primarily conservative strategy, enoxaparin has 
been proven superior to unfractioned heparin (UFH). With early invasive strategy providing 
better clinical outcome compared with conservative strategy, the effectiveness of enoxaparin 
in reducing death and MI rates is now being reconsidered in the era of poly-pharmacotherapy, 
early percutaneous coronary interventions and drug eluting stents. Bleeding complications can 
be minimized by avoiding cross-over from UFH to enoxaparin or vice versa, or by reducing 
the dosage of enoxaparin. We review the studies of enoxaparin and discuss its current role in 
the contemporary treatment of NSTE-ACS.
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Introduction
With the ongoing development of mechanical revascularization approaches and new 
generation pharmacological agents, the use of well established therapeutic cornerstones 
such as unfractioned heparins (UFH) and low-molecular-weight heparins (LMWH) is 
being reconsidered. In this review, we focus on the role of enoxaparin in view of the 
most recent clinical trials (see Table 1) for anticoagulant therapies in non-ST elevation 
acute coronary syndrome (NSTE-ACS).
Pathophysiology of the culprit lesion
Acute coronary syndrome refers to cardiovascular disorders characterized by plaque 
rupture or erosion with consequent intracoronary thrombus formation. Exposure of 
collagen and tissue factor to the circulating blood leads to activation of the intrinsic 
and extrinsic coagulation system, thereby generating thrombin (factor IIa). Thrombin 
transforms circulating ﬁ  brinogen into ﬁ  brin, which in turn polymerizes, consolidating 
the developing thrombus. The ﬁ  brin strands are further reinforced by cross-linking with 
factor XIIIa, derived both from plasma and platelet granules. In addition to activating 
a positive feedback loop that initiates further factor X activation, thrombin itself is 
among the most potent direct stimulators of platelet activation and recruitment. The 
pivotal role of this protein led to sustained efforts to develop therapies that block 
thrombin generation or activity.
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Enoxaparin in NSTEMI
Indirect thrombin inhibitors
UFH is a glycosaminoglycane composed of polysaccharides 
of mixed-length and molecular weights varying from 3000 to 
50 000 Da. UFH is an indirect thrombin inhibitor, requiring 
binding to the cofactor antithrombin III (AT III) before being 
fully activated. The UFH/AT III complex binds to thrombin 
leading to its deactivation. In aspirin-treated patients with 
ACS, UFH is associated with a 30% additional reduction in 
the risk of recurrent myocardial infarction (MI) at 1 week 
(Eikelboom et al 2000). Shortcomings of UFH include 
individual saturation dosages, the inability to inactivate clot-
bound thrombin, direct platelet activation, immunologically 
mediated thrombocytopenia, inactivation by plasma proteins 
and platelet factor 4, rebound increase after cessation of 
infusion, and, ultimately, a narrow therapeutic window with 
the need for close laboratory monitoring of its anticoagulant 
effect. These limitations may be especially problematic in 
the context of ACS, in which patients are already at high risk 
of ischemic events because of heightened baseline platelet 
reactivity, pre-existing thrombus, and an inﬂ  ammatory state 
characterized by the release of cellular proteins into the 
bloodstream (Fuster et al 1992).
To overcome these limitations, better heparin prepara-
tions led to the development of LMWH. LMWH are fractions 
of standard heparins with average molecular weights between 
4000 and 6000 Da, glycosaminglycans with chains of alter-
nating residues of D-glucosamine and uronic acid. Because 
of their biophysical difference they inactivate thrombin less 
and are more selective inhibitors of factor Xa. The anti-Xa/
anti IIa ratio of LMWH (ardeparin, dalteparin, nandroparin, 
reviparin, tinzaparin, and enoxaparin) varies according to the 
preparation between 1.5 and is highest for enoxaparin with 
3.8 (Weitz 1997). Enoxaparin has greater bioavailability with 
longer half-life and higher effectiveness, providing a more 
predictable anticoagulant response than UFH. 
LMWH in NSTE-ACS
Data comparing UFH with LMWH in randomized, controlled 
trials for the treatment of NSTE-ACS are best for the most 
commonly used compound enoxaparin (Petersen et al 2004). 
Studies using other LMWH (nadroparin in FRAX.I.S [The 
Frax.I.S. Study Group 1999]; dalteparin in FRIC [Klein et al 
1997] and FRISC II [F Ragmin and Fast Revascularisation 
during InStability in Coronary artery disease (FRISC II) 
1999; FRagmin Fast Revascularisation during In Stability 
in Coronary artery disease (FRISC II) 1999]) have been 
disappointing.
Enoxaparin without glycoprotein 
IIb/IIIa inhibitors 
ESSENCE (Eﬁ  cacy and Safety of Subcutaneous Enoxaparin 
in Non-Q-Wave Coronary Events) (Cohen et al 1997) and 
TIMI 11B (Thrombolysis in Myocardial Infarction 11B) 
(Antman et al 1999) were the ﬁ  rst large clinical trials compar-
ing enoxaparin with UFH. They were conducted in the era 
of predominantly conservative management of NSTE-ACS 
as less than 20% underwent percutaneous coronary inter-
vention (PCI). The primary endpoint at 14 days was lower 
with enoxaparin (composite triple endpoint of death, MI or 
reinfarction, or recurrent angina; n = 3171; 19.8% vs 16.6%; 
p = 0.019) and remained lower at 30 days in ESSENCE and 
similarly, in TIMI-11B (death, MI, or urgent revasculariza-
tion by 8 days; n = 3910; 12.4% vs 14.5%; p = 0.048). In 
a meta-analysis (Antman et al 1999) of the two trials, the 
relative risk reduction was around 20% in rates of death and 
MI in patients treated with enoxaparin from day 2 to 43. The 
beneﬁ  t of enoxaparin was achieved with an increase in minor 
bleeding (18.4% vs 14.8%; p = 0.001) in ESSENCE (Cohen 
et al 1997) and in major bleeding (1.4% vs 2.1%; p < 0.001) 
in TIMI 11B (Antman et al 1999). 
In view of these trials enoxaparin and UFH were both 
recommended as class I indications in patients undergo-
ing medical therapy for ACS without GPIIb/IIIa inhibitors 
(Braunwald et al 2002) by the Association Task Force on 
Practice Guidelines American College of Cardiology/Ameri-
can Heart 2002, and enoxaparin was made preferable to UFH 
(class IIa, level of evidence A).
Enoxaparin with glycoprotein IIb/
IIIa Inhibitors 
Enoxaparin evolved in parallel, but separately, with the plate-
let glycoprotein (GP) IIb/IIIa inhibitor era. Thus, subsequent 
studies have used a more aggressive approach using early 
revascularization and more frequent use of clopidogrel and 
GP IIb/IIIa antagonists. There is a substantial and growing 
body of evidence supporting the use of enoxaparin in the 
cardiac catheterization laboratory both with and without GP 
IIb/IIIa inhibitors.
The ACUTE II (Anti-Thrombotic Combination Using 
Tiroﬁ  ban and Enoxaparin) trial (Cohen et al 2002) included 
525 patients with NSTE-ACS who were randomized to 
receive enoxaparin or UFH on top of tiroﬁ  ban and aspirin. 
The study was powered to assess bleeding incidences. The 
primary endpoint of death or MI after 30 days occurred with 
similar frequency in both groups (9.0% with enoxaparin vs Vascular Health and Risk Management 2007:3(2) 224
Schmidt-Lucke and Schultheiss
9.2% with UFH; p = 0.77). TIMI major bleeding rates were 
0.3% with enoxaparin vs 1.0% with UFH (OR 3.0; 95% CI, 
0.30–33.8). Fewer than 30% of patients underwent coronary 
angiography while on study medication.
In 748 patients with high-risk NSTE-ACS enrolled in the 
INTERACT (Integrillin and Enoxaparin Randomized Assess-
ment of Acute Coronary Syndrome Treatment) trial (Good-
man et al 2003), enoxaparin improved outcomes compared 
with UFH on the background of aspirin and eptiﬁ  batide. The 
primary safety endpoint of non-CAGB related major bleeding 
at 96 hours was 2% in enoxaparin vs 5% with UFH (p = 0.03). 
Although not powered to prove efﬁ  cacy, the endpoint of death 
and/or MI at 30 days was 5% with enoxaparin vs 9% with 
UFH (OR 0.52; 95% CI, 0.30–0.96; p = 0.031). Less than 
15% of patients enrolled underwent coronary angiography 
within 48 hours of randomization. 
The NICE-3 (National Investigators Collaborating on 
Enoxaparin-3) (Ferguson et al 2003) study was a open-label 
observational study analyzing the combination of enoxaparin 
with abciximab, tiroﬁ  ban, or eptiﬁ  batide in 628 patients. 
The primary end point was the incidence of major bleeding 
not related to coronary artery bypass graft (CABG) surgery. 
Forty-ﬁ  ve per cent of patients enrolled underwent PCI. The 
30-day incidence of non-CABG major bleeding was 1.9%, 
and was not signiﬁ  cantly higher than a prespeciﬁ  ed historical 
control rate of 2.0%. The study was not randomized but used 
a historical cohort as controls, and as such these results must 
be interpreted with caution. 
The Phase A of the A to Z trial (Blazing et al 2004) 
(Agrastat to Zocor) assessed the efﬁ  cacy and safety of 
enoxaparin with the GP IIb/IIIa inhibitor tiroﬁ  ban compared 
with UFH with tiroﬁ  ban in 3987 patients with ACS. In this 
trial, cardiac catheterization was performed in only 61% of 
patients at a mean of 4.5 days. The study was powered to 
test the safety and superiority of enoxaparin over UFH. In 
this setting, enoxaparin was a suitable alternative to UFH 
with a 12% relative and a 1% absolute reduction (8.4% vs 
9.4%, p = 0.23) in the primary endpoint consisting of death, 
recurrent MI, or refractory angina after 7 days (Blazing 
et al 2004) (OR 0.88; 95% CI, 0.71–1.08). The occurrence 
of the safety endpoint (consisting of TIMI major, minor, or 
unknown site) was similar in both treatment groups (3% with 
enoxaparin vs 2.2% with UFH, p = 0.13). In this study, 45% 
of the patients were prespeciﬁ  ed to be treated conservatively 
(de Lemos et al 2004). In this cohort, enoxaparin reduced the 
absolute risk of the primary endpoint signiﬁ  cantly (7.7% vs 
10.6%, OR 0.72; 95% CI, 0.53–0.99, p = 0.04), whereas at 
30 days, there was only a trend favoring enoxaparin (11% 
vs 13%, p = 0.10). The overall occurrence of bleeding was 
not different between the treatment groups in the conserva-
tive subgroup of this study, although there was a small, but 
statistically signiﬁ  cant increase in TIMI major bleeding in the 
enoxaparin group (0.8% with enoxaparin vs 0% with UFH, 
p = 0.02). In the 55% of patients prespeciﬁ  ed for an early 
invasive treatment strategy, the absolute risk of the primary 
endpoint was similar in both groups (8.8% vs 8.5).
It appears from these studies that for patients with NSTE-
ACS undergoing early conservative strategy combined with 
a GPIIb/IIIa inhibitor, enoxaparin is at least as effective as, 
or may even be better than, UFH in reducing death, MI, 
and refractory angina, at cost of an increased risk of major 
bleeding. The updated American College of Cardiology 
(ACC)/American Heart Association (AHA) guidelines for the 
management of patients with NSTE ACS (released in March 
2002) give class IA recommendations for early invasive 
management combined with GP IIb/IIIa inhibitor therapy 
but do not differentiate between LMWH and UFH in the 
class IA recommendation for concomitant antithrombotic 
therapy. The results of the SYNERGY and A to Z studies 
have not yet found their way into AHA/ACC guidelines 
(Braunwald et al 2002).
Enoxaparin in acute interventions
With an early invasive strategy providing better clinical 
outcome than a conservative strategy, the paradigm of ACS 
management has shifted in favor of early (within 48 hours 
of admission) cardiac catheterization, and studies have now 
been designed to meet these recommendations.
Several recent studies such as Evaluation of Prolonged 
Anti-thrombotic Pretreatment (cooling-off strategy) Before 
Intervention in Patients with Unstable Coronary Syndrome 
(ISAR-COOL) Trial (Neumann et al 2003), Comparison of 
Early Invasive and Conservative Strategies in Patients with 
Unstable Coronary Syndromes Treated with GP IIb/IIIa 
Inhibitor Tiroﬁ  ban (TACTICS TIMI-18) trial (Cannon et al 
2001), the Fragmin and fast Revascularization during instabil-
ity in Coronary artery disease multicenter study (FRISC II) 
(F Ragmin and Fast Revascularisation during InStability 
in Coronary artery disease (FRISC II) 1999), The British 
Heart Foundation RITA-3 trial (Fox et al 2005) have pro-
vided evidence for the beneﬁ  t of early revascularization in 
NSTE-ACS. However, there is still dispute whether, given 
optimized medical therapy, an early invasive strategy is 
superior to a selectively invasive strategy in patients with 
acute coronary syndromes without ST-segment elevation 
and with an elevated cardiac troponin T level (de Winter Vascular Health and Risk Management 2007:3(2) 225
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et al 2005). Current guidelines (Braunwald et al 2002) recom-
mend an early invasive strategy for patients without serious 
comorbidities who have acute coronary syndromes without 
ST-segment elevation, with an elevated cardiac troponin 
T level, impaired cardiac function, sustained ventricular 
tachycardia, or PCI within the 6 months.
The CRUISE (Bhatt et al 2003) (Coronary Revascular-
ization Using Integrilin and Single Bolus Enoxaparin) study 
was designed to assess whether the use of enoxaparin during 
elective or urgent PCI increased bleeding compared with 
unfractionated heparin, in addition to background therapy 
with eptiﬁ  batide. Of the 261 patients enrolled, 98% and 
99% randomized to 0.75 mg/kg enoxaparin intraveneously 
or UFH, respectively, had PCI performed. Around 46% un-
derwent urgent PCI for NSTE-ACS in either group. Stents 
were placed in 86.5% and 85.4% of the enoxaparin and 
UFH arms, with thienopyridine pretreatment in 94.6% and 
93.8%, respectively. The primary endpoint of the study, the 
bleeding index, was 0.8 with enoxaparin and 1.1 with UFH 
(p = 0.15). The study demonstrated similar rates of vascu-
lar access complications, angiographic complications, and 
ischemic complications. 
The SYNERGY (Superior Yield of the New Strategy of 
Enoxaparin, Revascularisation and GP IIb/IIIa Inhibitors) 
trial (SYNERGY Trial Investigators 2004), designed to 
deﬁ  ne the role of enoxaparin in high risk patients with NSTE-
ACS managed with an early invasive approach, enrolled 
9978 patients. The primary efﬁ  cacy outcome (death or MI) 
during the ﬁ  rst 30 days occurred in 14.0% with enoxaparin 
and 14.5% with UFH (OR, 0.96; 95% CI, 0.86–1.06). More 
bleeding was observed with enoxaparin, with a statistically 
signiﬁ  cant increase in TIMI  major bleeding (9.1% vs 7.6%, 
p = 0.008). Forty-six per cent of patients underwent PCI 
within a median time of 22 hours. A total of 58.8% of patients 
received GPIIb/IIIa.
An important message from SYNERGY is that chang-
ing antithrombotic agents from LWMH to UFH or vice 
versa leads to an increased bleeding and less clinical beneﬁ  t 
(SYNERGY Trial Investigators 2004). In the subgroup with 
no cross-over, there was a beneﬁ  t with enoxaparin reducing 
the primary endpoint (OR 0.82; 95% CI, 0.72–0.94). 
In the recently presented STEEPLE (Safety and Efﬁ  cacy 
of intravenous Enoxaparin in Elective Percutaneous Coro-
nary Intervention) trial (Montalescot et al 2006), efﬁ  cacy 
of a reduced intravenous enoxaparin dose (0.5 mg/kg) and 
0.75 mg/kg enoxaparin given once vs UFH were compared in 
non-urgent PCI in 3528 patients. GPIIb/IIIa were used in 41% 
of patients. The primary endpoint of non-CABG major or 
minor bleeding was lower in those groups treated with enoxa-
parin (6.0% for the reduced dose [p = 0.014 vs UFH], 6.6% 
for regular dose [p = 0.052 vs UFH], and 8.7% for UFH); 
major bleeding occurred in 1.2% of each of the enoxaparin 
groups (p = 0.005 and p = 0.007, respectively, vs UFH) and 
2.8% in the UFH group. The composite endpoint of non-
CABG major bleed through 48 hours, all-cause mortality, 
MI, or urgent target vessel revascularization at 30 days was 
numerically lower among the two enoxaparin groups (7.2% 
and 7.9%) compared with the UFH group (8.4%). Patient 
enrollment in the enoxaparin 0.5 mg/kg treatment group was 
discontinued near the end of the trial, due to a difference in 
mortality between the three groups (p = 0.02). The authors 
conclude that enoxaparin at a lower dose in the catheteriza-
tion laboratory may result in lower bleeding events.
Whether the results of this study may be transferred to the 
setting of unstable angina remains to be evaluated.
In a randomized, controlled study 966 patients with 
coronary heart disease (Chen et al 2006), including 29.2% 
with NSTE-ACS, were randomized to enoxaparin (1 mg/kg 
bd) and UFH prior to catheterization. Four hundred and ﬁ  fty-
ﬁ  ve patients underwent PCI. The incidence of hematoma on 
the puncture site was signiﬁ  cantly higher in the UFH group 
than that in the enoxaparin group (7.3 vs 3.1, respectively 
p = 0.03). The incidence of death, MI, revascularization at 30 
days was 0 in enoxaparin group and 0.43% in UFH group, 
the study clearly being underpowered for these endpoints. 
The authors found that enoxaparin was safe and efﬁ  cient 
during PCI.
A meta-analysis evaluated 6 large-scale randomized 
controlled trials (ESSENCE, TIMI-11B, ACUTE II, INTER-
ACT, A to Z, and SYNERGY) comparing enoxaparin and 
UFH in NSTE-ACS with the endpoints of all-cause death 
and non-fatal MI, transfusion, and major bleeding (Petersen 
et al 2004). In 21946 patients, a statistically signiﬁ  cant 
reduction of the combined endpoint death or MI at 30 days 
was observed (10.1% vs 11%; OR 0.91; 95% CI, 0.83–0.99; 
number needed to treat: 107) with enoxaparin. No difference 
was found in blood transfusion (OR 1.01; 95% CI, 0.89–1.14) 
or major bleeding (OR 1.04; 95% CI, 0.83–1.30) at 7 days 
after randomization(Petersen et al 2004).
ACUITY (Acute Catherisation and Urgent Interven-
tion Triage strategy) (Stone et al 2004) trial is an ongoing 
large-scale, prospective, multicenter, randomized study 
designed to determine the optimal anticoagulation regimen 
in patients with moderate- to high-risk ACS undergoing an 
early invasive strategy. Patients (13800) will be assigned 
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inhibition, vs bivalirudin + GPIIb/IIIa inhibition, vs bivaliru-
din + provisional IIb/IIIa inhibition. Cardiac catheterization 
is to be performed within 72 hours. 
The trial is powered to examine whether: (1) bivalirudin 
with routine GPIIb/IIIa inhibition, compared with heparin 
(either UFH or enoxaparin) with routine GPIIb/IIIa in-
hibition, provides either non-inferior or superior overall 
30-day clinical outcomes (composite incidence of death, 
MI, unplanned revascularization for ischemia, plus major 
bleeding); and (2) bivalirudin alone reduces major bleeding 
compared with heparin (either UFH or enoxaparin) with 
routine GPIIb/IIIa inhibition. 
Efﬁ  cacy endpoints in the above-mentioned studies were 
death and the combined endpoint of death or non-fatal MI. 
In ESSENCE recurrent angina and successful resuscitation 
of sudden death counted as death. Brieﬂ  y, the deﬁ  nitions of 
spontaneous MI incorporated creatinin kinase-MB level of 
greater the upper limit of normal (ULN) in ESSENCE, TIMI 
11B, and INTERACT, and 2 or more times the upper limit of 
normal in ACUTE and SYNERGY. Diagnosis of MI occurring 
around the time of PCI incorporated a criterion of ≥ 3 times 
the ULN of CK-MB and ≥ 5 times the ULN in the diagnosis 
of post-CABG MI. All studies included electrocardiographic 
deﬁ  nitions of MI. Different numbers in the efﬁ  cacy endpoints 
of the single studies reﬂ  ect the constant evolvement in the 
management of ACS in the past decade. Advances include 
an early invasive management strategy, improved stenting 
technology, adjunctive pharmacotherapy, and routine use 
of GPIIb/IIIa antagonists and thienopyridines. Furthermore, 
patients receiving prerandomization antithrombin therapy 
(from 30% in TIMI 11B to 75% in SYNERGY), or inclusion 
of the CABG surgery complications modify the number of 
the prespeciﬁ  ed efﬁ  cacy endpoints.
The safety endpoints in these studies were major bleeding 
and transfusion. The deﬁ  nitions of major hemorrhage incor-
porated bleeding that resulted in death, retroperitoneal bleed-
ing, a decrease of hemoglobin of ≥ 3 g/dL in INTERACT and 
CRUISE, and additionally, requirement of ≥ 2 units of blood 
or intraocular and intracranial bleeding in ESSENCE and 
TIMI 11b. ACUTE II, A to Z, and SYNERGY deﬁ  ned major 
bleeding as a decrease of hemoglobin of ≥ 5 g/dL. STEEPLE 
assessed bleeding rates up to 48 hours, whereas in the study 
of Chen et al major bleeding was not prespeciﬁ  ed, and only 
hematoma at the puncture site were reported. Differences 
regarding the incidence of bleeding may refer either to the 
duration of follow-up and data collection, to the deﬁ  nition 
of major hemorrhage, the concomitant use of GPIIb/IIIa in-
hibitors, patients receiving prerandomization therapy, or that 
CABG surgery-related bleeding was not assessed (ACUTE 
II and A to Z) . In A to Z and SYNERGY, switching anti-
thrombin therapy evoked excess bleeding complications. In 
STEEPLE reduction of the dosage of enoxaparin resulted in 
lower incidence of bleeding complications. 
Registries
Systematic studies that compared the patterns of use of 
unfractionated heparin (UFH) and low-molecular-weight 
heparin (LMWH) in patients with acute coronary syndromes 
(ACS) have been carried out in the “real-world” setting. 
In the GRACE (Global Registry of Acute Coronary 
Events) (Klein et al 2003), the use of LMWH and UFH was 
analyzed in 13 231 ACS patients according to patient history, 
concomitant treatment, and invasive procedures. Results 
show that younger patients (<60 years), patients admitted to 
hospitals with PCI facilities, and patients undergoing invasive 
procedures were more likely to receive UFH, or both UFH 
and LMWH than LMWH alone (80.1% enoxaparin, 19.9% 
other LMWH). Patients receiving LMWH had signiﬁ  cantly 
lower rates of hospital mortality (p = 0.009) and major bleed-
ing (p < 0.0001). The authors conclude that UFH tends to be 
used more frequently than LMWH, but hospital outcomes 
appeared to be better with LMWH.
In a subanalysis from the CRUSADE Initiative (Bhatt 
et al 2004), LMWH and UFH were evaluated in high-risk 
NSTE ACS who had received early (<24 hours) GP IIb/IIIa 
inhibitor therapy and underwent early invasive management 
(Singh et al 2006). From a total of 11 358 patients treated 
at 407 hospitals in the US from January 2002 to June 2003, 
60.6% received UFH and 39.4% received LMWH. According 
to information of the Institute of Medical Statistics (IMS) 
Health, enoxaparin accounts for about 80% of the LMWH 
prescribed in the USA. Therefore it is likely that most of 
the LMWH usage documented in CRUSADE represents 
enoxaparin. Patients treated with UFH were more often 
admitted to a cardiology inpatient service (73.6% vs 65.5%, 
p < 0.0001) and more frequently underwent diagnostic cath-
eterization (91.8% vs 85.9%, p < 0.0001) and PCI (69.7% 
vs 56.9%, p < 0.0001) than patients treated with LMWH. 
The point estimate of the adjusted risk of in-hospital death 
or reinfarction was slightly lower among patients treated 
with LMWH (OR 0.81, 95% CI 0.67–0.99) and the risk of 
red blood cell transfusion was similar (OR 1.01, 95% CI 
0.89–1.15). Among patients who underwent PCI within 48 
hours, adjusted rates of death (OR 1.14, 95% CI 0.71–1.85), 
death or reinfarction (OR 0.93, 0.67–1.31), and transfusion 
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In a retrospective analysis of the prospective ACOS 
registry (Zeymer et al 2006), the outcome of high-risk 
patients with NSTE-ACS (according to those in SYNERGY) 
who were treated with enoxaparin or unfractionated heparin 
between July 2000 and November 2002 in 153 hospitals 
in Germany were compared. Twenty-ﬁ  ve per cent of 4806 
patients were treated with enoxaparin and 75% with unfrac-
tionated heparin. There were no differences between groups 
in baseline characteristics. There was a signiﬁ  cant decrease 
in the combined endpoint of death or non-fatal reinfarc-
tion with enoxaparin in the entire study group (OR 0.51, 
95% CI0.37–0.70) and in subgroups treated with early PCI 
(n = 1333, OR 0.36, 95% CI 0.17–0.80), CABG (n = 270, 
OR 0.31, 95% CI 0.04–2.42), or conservatively (n = 3,203, 
OR 0.57, 95% CI 0.40–0.81). There was no signiﬁ  cant 
increase in severe bleeding complications with enoxaparin 
(5.2% vs 4.5%). 
In conclusion, in clinical practice, in unselected patients 
with NSTE-ACS who are treated conservatively or with early 
PCI, early treatment with enoxaparin is associated with a 
signiﬁ  cant decrease in the combined endpoint of in-hospital 
death and reinfarction, without a signiﬁ  cant increase in severe 
bleeding complications. Less than 30% of patients received 
LMWH in “real life”. Despite signiﬁ  cant better outcome with 
enoxaparin, patients undergoing invasive procedures or PCI 
more often received UFH.
Direct thrombin inhibitors (DTI) 
and pentasaccharides
The optimal combination of antiplatelet and antithrombin 
regimens that maximizes efﬁ  cacy and minimizes bleeding 
among patients with NSTE-ACS undergoing PCI are under 
investigation in several trials involving other substances. In 
the recently published OASIS-5 trial, fondaparinux, a syn-
thetic pentasaccharide, challenged the role of heparins and 
enoxaparin. Large-scale trials comparing enoxaparin with 
DTI are being performed currently. 
In contrast to UFH and LMWH, direct thrombin inhibitors 
are able to inhibit both circulating and clot-bound thrombin. 
Bivalirudin, a synthetic, thrombin-speciﬁ  c anticoagulant 
approved for patients with unstable angina undergoing PCI 
(Bittl et al 2001; Lincoff et al 2003), is a bivalent DTI with 
linear kinetics that binds speciﬁ  cally to thrombin at its active 
catalytic site and at the exosite-1 docking locus.
In a meta-analysis (Kong et al 1999) of 4 randomized, 
controlled trials (n = 4973) comparing bivalirudin with UFH 
in patients with ACS treated either conservatively or with 
angioplasty (though before the GPIIb/IIIa era), bivalirudin sig-
niﬁ  cantly reduced the composite incidence of death or MI by 
23% (p = 0.02) and major hemorrhage by 59% (p = 0.01).
The PROTECT–TIMI-30 (Randomized Trial to Evaluate 
the Relative PROTECTion against Post-PCI Microvascular 
Dysfunction and Post-PCI Ischemia among Anti-Platelet 
and Anti-thrombotic Agents–Thrombolysis In Myocardial 
Infarction-30) is a randomized, open label, parallel-group, in-
ternational, multicenter study to evaluate the angiographic and 
ischemic efﬁ  cacy of eptiﬁ  batide in combination with a heparin 
(UFH or enoxaparin 0.5 mg/kg iv) compared with bivalirudin 
monotherapy in 857 high-risk patients with unstable angina 
or non-ST segment elevation MI (NSTEMI) undergoing 
PCI (Gibson et al 2006). Eptiﬁ  batide improved myocardial 
perfusion and reduced the duration of post-PCI ischemia but 
was associated with higher minor bleeding (2.5% vs 0.4%, 
p = 0.027) and transfusion rates (4.4%–0.4%, p = 0.001).
The OASIS-5 (Fifth Organization to Assess Strategies in 
Acute Ischemic Syndromes) trial (MICHELANGELO OASIS 
5 Steering 2005; The Fifth Organization to Assess Strategies in 
Acute Ischemic Syndromes Investigators 2006) compared the 
efﬁ  cacy and safety of fondaparinux and enoxaparin in 20 078 
high-risk patients with unstable angina or MI without ST-seg-
ment elevation. Fondaparinux selectively binds antithrombin 
and causes rapid and predictable inhibition of factor Xa. The 
rate of major bleeding at 9 days was markedly lower with 
fondaparinux than with enoxaparin (2.2% vs 4.1%; OR, 0.52; 
p < 0.001). The primary endpoint (death, MI, or refractory 
ischemia at 9 days) occurred in 5.8% vs 5.7% with enoxaparin 
(OR in the fondaparinux group, 1.01; 95% CI, 0.90–1.13), 
satisfying the non-inferiority criteria. 
Conclusion
Optimal therapy of patients with NSTE-ACS comprises the 
combined use of coronary angiography and PCI within 24–48 
hours, and combined administration of antithrobotic agents, 
like antithrombins and platelet inhibitors. It reduces ischemic 
coronary events but also increases bleeding in patients with 
acute coronary syndromes.
Enoxaparin has been shown to decrease ischemic com-
plications in patients with acute coronary syndromes without 
ST elevations who are treated conservatively. Enoxaparin has 
been shown to be equally effective as unfractionated heparin 
in high-risk ACS patients with an early invasive approach. 
It seems of utmost importance to avoid cross-over from 
enoxaparin to UFH and vice versa. 
The above-described randomized clinical trials highlight 
the relevance of enoxaparin in the setting of acute coronary 
interventions in high risk patients with NSTE-ACS. Vascular Health and Risk Management 2007:3(2) 228
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